|
FDA Advisory Committee votes on investigational medicine metreleptin
|
12 December 2013 |
|
AstraZeneca to invest £120 million in new manufacturing facility to produce Zoladex
|
11 November 2013 |
|
AstraZeneca advances MedImmune's benralizumab to Phase III in severe asthma
|
30 October 2013 |
|
AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
|
15 October 2013 |
|
AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment
|
11 October 2013 |
|
AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
|
11 September 2013 |
|
MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune
|
26 August 2013 |
|
AstraZeneca PLC second quarter and half year results 2013
|
01 August 2013 |
|
AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application
|
25 July 2013 |
|
AstraZeneca collaborates with Cambridge medical research institutions to advance cancer research
|
09 July 2013 |